RhumbLine Advisers’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $105K | Buy |
|
|||||
|
2023
Q4 | $55.7K | Hold |
|
|||||
|
2023
Q3 | $69.4K | Buy |
|
|||||
|
2023
Q2 | $161K | Buy |
|
|||||
|
2023
Q1 | $227K | Buy |
|
|||||
|
2022
Q4 | $275K | Buy |
|
|||||
|
2022
Q3 | $708K | Buy |
|
|||||
|
2022
Q2 | $640K | Buy |
|
|||||
|
2022
Q1 | $607K | Sell |
|
|||||
|
2021
Q4 | $753K | Sell |
|
|||||
|
2021
Q3 | $903K | Buy |
|
|||||
|
2021
Q2 | $805K | Buy |
|
|||||
|
2021
Q1 | $828K | Sell |
|
|||||
|
2020
Q4 | $889K | Buy |
|
|||||
|
2020
Q3 | $437K | Sell |
|
|||||
|
2020
Q2 | $624K | Buy |
|
|||||
|
2020
Q1 | $325K | Buy |
|
|||||
|
2019
Q4 | $434K | Buy |
|